Blood test may predict Sjögren's severity

NCT ID NCT07414667

Not yet recruiting Knowledge-focused Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether measuring a specific antibody, anti-Ro52, in the blood of people with Sjögren's syndrome can help predict who will develop serious problems like lymphoma or organ damage. Researchers will follow 150 patients over time to see if higher antibody levels are linked to worse disease activity. The goal is to improve how doctors assess risk and tailor treatment for each patient.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a blood test that helps doctors identify Sjögren's patients at higher risk for serious complications, enabling earlier and more personalized care.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly improve health. The findings may not change current practice if the antibody levels don't reliably predict outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SJÖGREN'S SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Sjogren syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SJÖGREN'S SYNDROME

Contacts and locations

Locations

Université de Nancy

Vandœuvre-lès-Nancy, 54500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.